Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AMPH NASDAQ:CRGX NASDAQ:DSGN NASDAQ:REPL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMPHAmphastar Pharmaceuticals$19.30-1.5%$19.26$16.65▼$31.26$863.78M0.89426,045 shs409,242 shsCRGXCARGO Therapeutics$4.47$4.49$3.78▼$4.77$216.17M0.31.43 million shsN/ADSGNDesign Therapeutics$11.78-2.3%$12.44$3.76▼$17.25$753.23M1.58913,912 shs469,883 shsREPLReplimune Group$10.75-2.3%$9.06$1.50▼$12.50$923.40M0.863.22 million shs1.63 million shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMPHAmphastar Pharmaceuticals-0.20%+4.15%+4.15%-6.67%-7.55%CRGXCARGO Therapeutics0.00%0.00%0.00%0.00%-1.11%DSGNDesign Therapeutics+1.60%-11.78%-3.05%-9.80%+197.78%REPLReplimune Group+4.66%+11.45%+7.95%+384.58%-10.71%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMPHAmphastar Pharmaceuticals$19.30-1.5%$19.26$16.65▼$31.26$863.78M0.89426,045 shs409,242 shsCRGXCARGO Therapeutics$4.47$4.49$3.78▼$4.77$216.17M0.31.43 million shsN/ADSGNDesign Therapeutics$11.78-2.3%$12.44$3.76▼$17.25$753.23M1.58913,912 shs469,883 shsREPLReplimune Group$10.75-2.3%$9.06$1.50▼$12.50$923.40M0.863.22 million shs1.63 million shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMPHAmphastar Pharmaceuticals-0.20%+4.15%+4.15%-6.67%-7.55%CRGXCARGO Therapeutics0.00%0.00%0.00%0.00%-1.11%DSGNDesign Therapeutics+1.60%-11.78%-3.05%-9.80%+197.78%REPLReplimune Group+4.66%+11.45%+7.95%+384.58%-10.71%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMPHAmphastar Pharmaceuticals 1.63Reduce$22.0013.99% UpsideCRGXCARGO Therapeutics 0.00N/AN/AN/ADSGNDesign Therapeutics 2.88Moderate Buy$16.5040.07% UpsideREPLReplimune Group 2.00Hold$8.13-24.42% DownsideCurrent Analyst Ratings BreakdownLatest CRGX, DSGN, AMPH, and REPL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/20/2026REPLReplimune Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)7/17/2026DSGNDesign Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/8/2026AMPHAmphastar Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)7/2/2026REPLReplimune Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/30/2026REPLReplimune Group BMO Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeUnderperform ➝ Outperform$16.006/30/2026REPLReplimune Group WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$6.00 ➝ $9.006/29/2026AMPHAmphastar Pharmaceuticals Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral ➝ Underperform$25.00 ➝ $20.006/26/2026REPLReplimune Group JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Overweight$17.006/22/2026AMPHAmphastar Pharmaceuticals Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell6/18/2026REPLReplimune Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/3/2026REPLReplimune Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)(Data available from 7/22/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMPHAmphastar Pharmaceuticals$719.89M1.18$4.20 per share4.60$17.17 per share1.12CRGXCARGO TherapeuticsN/AN/AN/AN/A$4.91 per shareN/ADSGNDesign TherapeuticsN/AN/AN/AN/A$3.73 per shareN/AREPLReplimune GroupN/AN/AN/AN/A$2.01 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMPHAmphastar Pharmaceuticals$98.09M$1.6611.636.593.8511.00%15.12%7.14%8/6/2026 (Estimated)CRGXCARGO Therapeutics-$167.50M-$4.64N/AN/AN/AN/A-43.21%-37.26%N/ADSGNDesign Therapeutics-$69.79M-$1.20N/AN/AN/AN/A-33.07%-31.29%8/6/2026 (Estimated)REPLReplimune Group-$313.94M-$3.38N/AN/AN/AN/A-128.57%-82.35%8/6/2026 (Estimated)Latest CRGX, DSGN, AMPH, and REPL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2026Q2 2026AMPHAmphastar Pharmaceuticals$0.63N/AN/AN/A$179.71 millionN/A8/6/2026Q2 2026DSGNDesign Therapeutics-$0.36N/AN/AN/AN/AN/A8/6/2026Q1 2027REPLReplimune Group-$0.66N/AN/AN/A$13.60 millionN/A6/29/2026Q4 2026REPLReplimune Group-$0.6613-$0.76-$0.0988-$0.76$3.57 millionN/A5/7/2026Q1 2026AMPHAmphastar Pharmaceuticals$0.70$0.42-$0.28$0.14$173.46 million$171.17 million4/28/2026Q1 2026DSGNDesign Therapeutics-$0.36-$0.29+$0.07-$0.29N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAMPHAmphastar PharmaceuticalsN/AN/AN/AN/AN/ACRGXCARGO TherapeuticsN/AN/AN/AN/AN/ADSGNDesign TherapeuticsN/AN/AN/AN/AN/AREPLReplimune GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMPHAmphastar Pharmaceuticals0.793.852.82CRGXCARGO TherapeuticsN/A12.3712.37DSGNDesign TherapeuticsN/A22.2822.28REPLReplimune Group0.634.794.79Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMPHAmphastar Pharmaceuticals65.09%CRGXCARGO Therapeutics93.16%DSGNDesign Therapeutics56.64%REPLReplimune Group92.53%Insider OwnershipCompanyInsider OwnershipAMPHAmphastar Pharmaceuticals29.60%CRGXCARGO Therapeutics2.92%DSGNDesign Therapeutics17.10%REPLReplimune Group5.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMPHAmphastar Pharmaceuticals1,97644.09 million31.04 millionOptionableCRGXCARGO Therapeutics11648.36 million46.95 millionN/ADSGNDesign Therapeutics4062.46 million51.78 millionOptionableREPLReplimune Group21083.94 million79.58 millionOptionableCRGX, DSGN, AMPH, and REPL HeadlinesRecent News About These CompaniesReplimune Group (NASDAQ:REPL) Shares Up 5.3% - Still a Buy?July 19 at 4:21 AM | americanbankingnews.comReplimune Group (NASDAQ:REPL) Shares Up 5.3% - Should You Buy?July 17, 2026 | marketbeat.comJohnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Replimune Group, Inc. (REPL)July 15, 2026 | globenewswire.comCandriam S.C.A. Buys Shares of 394,027 Replimune Group, Inc. $REPLJuly 15, 2026 | marketbeat.comTraders Purchase Large Volume of Replimune Group Put Options (NASDAQ:REPL)July 13, 2026 | marketbeat.comReplimune Group (NASDAQ:REPL) Shares Down 6.6% - What's Next?July 13, 2026 | marketbeat.comReplimune Group, Inc. Common Stock (REPL)July 8, 2026 | nasdaq.comAnalysts Offer Insights on Healthcare Companies: Replimune Group (REPL), Abivax SA Sponsored ADR (ABVX) and Larimar Therapeutics (LRMR)July 1, 2026 | theglobeandmail.comAnalysts Offer Insights on Healthcare Companies: Replimune Group (REPL) and Monopar Therapeutics Inc (MNPR)June 30, 2026 | theglobeandmail.comReplimune: Stock Buoyant On Third Try At RP1 Approval - FDA AdCom May Be CrucialJune 30, 2026 | seekingalpha.comReplimune Reports Fiscal Fourth Quarter and Year End 2026 Financial Results and Provides Corporate UpdateJune 29, 2026 | globenewswire.comReplimune’s RP1 BLA Resubmission Accepted for ReviewJune 28, 2026 | theglobeandmail.comReplimune Group Announces FDA Acceptance for Review of RP1 BLA Resubmission in Advanced MelanomaJune 26, 2026 | quiverquant.comQReplimune Announces FDA Acceptance of RP1 Biologics License Application Resubmission for Advanced MelanomaJune 26, 2026 | globenewswire.comReplimune: Modeling The Coin Flip Of FDA ApprovalJune 4, 2026 | seekingalpha.comInsider Selling: Replimune Group (NASDAQ:REPL) Insider Sells 12,000 Shares of StockJune 4, 2026 | insidertrades.comReplimune Group, Inc.: Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology ...June 1, 2026 | finanznachrichten.deReplimune Group, Inc.: Replimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical ...June 1, 2026 | finanznachrichten.deWhy Is REPL Stock Gaining In Pre-Market Today?June 1, 2026 | finance.yahoo.comREPL Stock Soars on Plans of BLA Resubmission for Melanoma Combo DrugJune 1, 2026 | zacks.comReplimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral ...May 31, 2026 | caledonianrecord.comCNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSK Hynix’s Nasdaq Listing Could Reset the AI Memory TradeBy Thomas Hughes | July 7, 20265 Tech Stocks to Buy on the July PullbackBy Thomas Hughes | June 29, 2026Micron’s Sudden Plunge May Be an AI Buying ChanceBy Jeffrey Neal Johnson | June 23, 2026Rocket Lab’s Stock Drop Comes With a Bullish TwistBy Ryan Hasson | July 10, 2026The AI Boom Has a Second Act—And It's Playing Out in OpticsBy Bridget Bennett | June 29, 2026CRGX, DSGN, AMPH, and REPL Company DescriptionsAmphastar Pharmaceuticals NASDAQ:AMPH$19.30 -0.29 (-1.48%) Closing price 04:00 PM EasternExtended Trading$19.31 +0.01 (+0.05%) As of 05:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.CARGO Therapeutics NASDAQ:CRGXCARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California.Design Therapeutics NASDAQ:DSGN$11.78 -0.28 (-2.32%) Closing price 04:00 PM EasternExtended Trading$11.70 -0.08 (-0.66%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.Replimune Group NASDAQ:REPL$10.75 -0.25 (-2.27%) Closing price 04:00 PM EasternExtended Trading$10.89 +0.14 (+1.30%) As of 07:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Robotaxi Mode Engaged: Tesla Starts Monetizing Its Florida Fleet Insider Moves Are Sending Mixed Signals Across the Tech Sector Boxabl Disrupts Housing With A Tiny Float IPO Small Caps Are Crushing the S&P 500—3 Stocks Still Worth Buying Velo3D Forges a New Reality After Its Sharp Stock Sell-Off Why Apple Could Be the Last One Standing in the Tech Wreck Archer and Anduril Put ACHR Stock on a New Defense Flight Path 3M's Redemption Arc: Can Q2 Earnings Change the Narrative? Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
